A New Ultrasound Protocol Uses NT-proBNP to Distinguish Heart Failure from Lung Disease in the ER
The LUSBI ultrasound protocol effectively distinguished cardiac from non-cardiac causes of shortness of breath, validated by the peptide biomarker NT-proBNP in 80 ER patients.
Quick Facts
What This Study Found
Researchers created the LUSBI protocol — combining lung ultrasound, BREST heart failure risk scores, and inferior vena cava measurements — to distinguish cardiac from non-cardiac causes of shortness of breath in the emergency department. The protocol was validated against NT-proBNP, a peptide biomarker for heart failure.
NT-proBNP values differed significantly across LUSBI protocol profiles (p=0.004), confirming that the protocol's ultrasound-based classifications align with biochemical evidence of heart failure. There was also a significant difference (p=0.001) in LUSBI profiles between patients categorized by central venous pressure.
The protocol proved effective for quickly confirming or ruling out a cardiac cause of breathing difficulty in 80 emergency department patients.
Key Numbers
n=80 · p=0.004 for NT-proBNP across LUSBI profiles · p=0.001 for CVP category differences · 2 groups: experimental (dyspneic) and control
How They Did This
Cross-sectional study in an emergency department. 80 patients divided into experimental (dyspnea as main complaint) and control groups. Each patient received lung ultrasound, inferior vena cava measurements, and BREST scoring to create LUSBI protocol profiles. NT-proBNP blood levels served as the biochemical reference standard for cardiac origin.
Why This Research Matters
Shortness of breath is one of the most common emergency department complaints, and quickly determining whether it's caused by heart failure or lung disease changes treatment entirely. The LUSBI protocol offers a rapid bedside approach using ultrasound that was validated against the gold-standard peptide biomarker NT-proBNP. This is relevant to peptide science because NT-proBNP — a fragment of brain natriuretic peptide — serves as the laboratory benchmark against which new diagnostic approaches are measured.
The Bigger Picture
NT-proBNP has become the go-to peptide biomarker for heart failure diagnosis, but blood tests take time. Point-of-care ultrasound protocols like LUSBI aim to provide immediate answers at the bedside. This study validates ultrasound findings against the peptide biomarker, showing how peptide-based laboratory tests serve as the benchmark for evaluating new diagnostic approaches in emergency medicine.
What This Study Doesn't Tell Us
Small sample size (80 patients) from a single emergency department. Cross-sectional design cannot establish the protocol's predictive accuracy over time. No comparison with established diagnostic algorithms like the Framingham criteria. The study was conducted at one center, limiting generalizability.
Questions This Raises
- ?How does the LUSBI protocol's diagnostic accuracy compare to NT-proBNP testing alone?
- ?Would combining LUSBI with rapid NT-proBNP point-of-care testing improve outcomes beyond either alone?
- ?Can this protocol reduce time-to-treatment in busy emergency departments?
Trust & Context
- Key Stat:
- p = 0.004 NT-proBNP levels — the gold-standard peptide biomarker for heart failure — differed significantly across the LUSBI protocol's diagnostic profiles, validating the ultrasound-based approach.
- Evidence Grade:
- Small single-center cross-sectional study with 80 patients. While statistically significant results were achieved, the small sample and lack of comparison with established diagnostic algorithms limit the evidence strength.
- Study Age:
- Published in 2024, this study reflects current point-of-care ultrasound capabilities and NT-proBNP testing standards. Relevant to ongoing efforts to integrate bedside tools with biomarker diagnostics.
- Original Title:
- The LUSBI Protocol (Lung Ultrasound/BREST Score/Inferior Vena Cava)-Its Role in a Differential Diagnostic Approach to Dyspnea of Cardiogenic and Non-Cardiogenic Origin.
- Published In:
- Medicina (Kaunas, Lithuania), 60(9) (2024)
- Authors:
- Dojcinovic, Boris, Banjac, Nada, Vukmirovic, Sasa, Dojcinovic, Tamara, Vasovic, Lucija V, Mihajlovic, Dalibor, Vasovic, Velibor
- Database ID:
- RPEP-08096
Evidence Hierarchy
Frequently Asked Questions
What is NT-proBNP and why is it used?
NT-proBNP is a peptide fragment released by heart muscle cells when the heart is under stress. Higher blood levels indicate heart failure. It's considered the gold-standard blood test for diagnosing heart failure and is used here to validate a new ultrasound-based diagnostic protocol.
Why not just use the blood test instead of ultrasound?
Blood tests like NT-proBNP take time to process in the lab, while ultrasound provides immediate results at the bedside. In an emergency, the minutes saved by a quick ultrasound assessment could change treatment decisions. Ideally, both tools are used together for the most accurate diagnosis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-08096APA
Dojcinovic, Boris; Banjac, Nada; Vukmirovic, Sasa; Dojcinovic, Tamara; Vasovic, Lucija V; Mihajlovic, Dalibor; Vasovic, Velibor. (2024). The LUSBI Protocol (Lung Ultrasound/BREST Score/Inferior Vena Cava)-Its Role in a Differential Diagnostic Approach to Dyspnea of Cardiogenic and Non-Cardiogenic Origin.. Medicina (Kaunas, Lithuania), 60(9). https://doi.org/10.3390/medicina60091521
MLA
Dojcinovic, Boris, et al. "The LUSBI Protocol (Lung Ultrasound/BREST Score/Inferior Vena Cava)-Its Role in a Differential Diagnostic Approach to Dyspnea of Cardiogenic and Non-Cardiogenic Origin.." Medicina (Kaunas, 2024. https://doi.org/10.3390/medicina60091521
RethinkPeptides
RethinkPeptides Research Database. "The LUSBI Protocol (Lung Ultrasound/BREST Score/Inferior Ven..." RPEP-08096. Retrieved from https://rethinkpeptides.com/research/dojcinovic-2024-the-lusbi-protocol-lung
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.